Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series

Figures & data

Table 1 Demographic, Clinical and Test Results of Four Patients

						IDT (mm)
						Linear			Macrocyclic
					Timing of Reaction (Minutes)	Ionic			Ionic	Non-ionic
Patient N°	Sex	Age (y)	Culprit GBCA	Type of Reaction		Gadopentetate Dimeglumine	Gadobenate Dimeglumine	Gadoxetate	Gadoterate Meglumine	Gadobutrol	Gadoteridol
						(Magnevist^®)	(MultiHance^®)	(Eovist^®)	(Dotarem^®)	(Gadovist^®)	(ProHance^®)
1	F	52	Gadoteridol (ProHance^®)	Angioedema	10’	Negative	Negative	ND	Negative	Negative	+ 7mm
2	F	55	Gadopentetate dimeglumine (Magnevist^®)	Dyspnea, urticaria	10’	+ 5mm	+ 5mm	ND	Negative	+ 4mm	Negative
3	F	44	Gadobenate dimeglumine (MultiHance^®)	Urticaria-angioedema	25’	+ 6mm	+	ND	Negative	Negative	ND
4	F	49	Gadobenate dimeglumine (MultiHance^®)	Dry cough, dyspnea, angioedema	5’	Negative	+ 5mm	Negative	+ 6mm	Negative	ND

Notes: Intradermal Test (1:10). +, positive followed by skin test wheals size in millimetres (the indicated diameters are calculated excluding the initial wheal after injection; IDT are regarded as positive if the size of the initial wheal had increased by at least 3 mm in diameter and was surrounded by erythema after 20 minutes).

Abbreviations: IDT, intradermal test; y, years; GBCAs, gadolinium-based contrast agents; F, female; ND, not done.

Figure 1 Case 1 gadoteridol IDT result with main size of wheal of 9 mm and flare of 4 cm starting from 2 mm after GBCA injection (histamine wheal of 4 mm and negative control wheal of 1 mm).